Classification and pharmacology of progestins

被引:368
作者
Schindler, AE
Campagnoli, C
Druckmann, R
Huber, J
Pasqualini, JR
Schweppe, KW
Thijssen, JHH
机构
[1] Univ Essen Gesamthsch Klinikum, Inst Med Forsch & Fortbildung, D-45147 Essen, Germany
[2] Osped Ginecol St Anna, I-10126 Turin, Italy
[3] Ameno Menopause Ctr, F-06000 Nice, France
[4] AKH Wien, Abt Gynakol Endokrinol, A-1090 Vienna, Austria
[5] Inst Puericulture, F-75014 Paris, France
[6] Ammerland Klin, Geburtshilfe & Gynakol Abt, D-26622 Westerstede, Germany
[7] Univ Utrecht, Med Ctr, Dept Endocrinol, NL-3508 AB Utrecht, Netherlands
关键词
progesterone; progestin; classification; biological effects; pharmacology;
D O I
10.1016/j.maturitas.2003.09.014
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydrogesterone), progesterone derivatives (i.e. medrogestone) 17alpha-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promegestone, trimegestone, nesterone), 49-nortestosterone derivatives norethisterone (NET), lynestrenol, levonorgestrel, desogestrel, gestodene, norgestimate, dienogest) and spironolactone derivatives (i.e. drospirenone). Some of the synthetic progestins are prodrugs, which need to be metabolized to become active compounds. Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S7 / S16
页数:10
相关论文
共 20 条
[1]  
Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
[2]  
Campagnoli C, 1996, J STEROID BIOCHEM, V59, P357, DOI 10.1016/S0960-0760(96)00183-5
[3]   INFLUENCE OF ROUTE OF ADMINISTRATION ON PROGESTERONE METABOLISM [J].
DELIGNIERES, B ;
DENNERSTEIN, L ;
BACKSTROM, T .
MATURITAS, 1995, 21 (03) :251-257
[4]  
GOLBS S, 2001, MENOPAUSE REV, V6, P31
[5]   Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [J].
Grady, D ;
Herrington, D ;
Bittner, V ;
Blumenthal, R ;
Davidson, M ;
Hlatky, M ;
Hsia, J ;
Hulley, S ;
Herd, A ;
Khan, S ;
Newby, LK ;
Waters, D ;
Vittinghoff, E ;
Wenger, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01) :49-57
[6]   Physiological action of progesterone in target tissues [J].
Graham, JD ;
Clarke, CL .
ENDOCRINE REVIEWS, 1997, 18 (04) :502-519
[7]   Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [J].
Hulley, S ;
Furberg, C ;
Barrett-Connor, E ;
Cauley, J ;
Grady, D ;
Haskell, W ;
Knopp, R ;
Lowery, M ;
Satterfield, S ;
Schrott, H ;
Vittinghoff, E ;
Hunninghake, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01) :58-66
[8]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[9]  
Kuhl H, 2001, Ther Umsch, V58, P527, DOI 10.1024/0040-5930.58.9.527
[10]  
KUHL H, 2001, MENOPAUSE REV, V6, P9